AU2012214672B2 - Lipoprotein complexes and manufacturing and uses thereof - Google Patents

Lipoprotein complexes and manufacturing and uses thereof Download PDF

Info

Publication number
AU2012214672B2
AU2012214672B2 AU2012214672A AU2012214672A AU2012214672B2 AU 2012214672 B2 AU2012214672 B2 AU 2012214672B2 AU 2012214672 A AU2012214672 A AU 2012214672A AU 2012214672 A AU2012214672 A AU 2012214672A AU 2012214672 B2 AU2012214672 B2 AU 2012214672B2
Authority
AU
Australia
Prior art keywords
apoa
lipid
population
lipoprotein
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012214672A
Other languages
English (en)
Other versions
AU2012214672A1 (en
Inventor
Rose ACKERMANN
Jean-Louis Dasseux
Daniela Carmen Oniciu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abionyx Pharma SA
Original Assignee
Cerenis Therapeutics Holding SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerenis Therapeutics Holding SA filed Critical Cerenis Therapeutics Holding SA
Publication of AU2012214672A1 publication Critical patent/AU2012214672A1/en
Application granted granted Critical
Publication of AU2012214672B2 publication Critical patent/AU2012214672B2/en
Priority to AU2015271986A priority Critical patent/AU2015271986B2/en
Priority to AU2018203258A priority patent/AU2018203258B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012214672A 2011-02-07 2012-02-06 Lipoprotein complexes and manufacturing and uses thereof Active AU2012214672B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2015271986A AU2015271986B2 (en) 2011-02-07 2015-12-21 Lipoprotein complexes and manufacturing and uses thereof
AU2018203258A AU2018203258B9 (en) 2011-02-07 2018-05-10 Lipoprotein complexes and manufacturing and uses thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161440371P 2011-02-07 2011-02-07
US61/440,371 2011-02-07
US201161452630P 2011-03-14 2011-03-14
US61/452,630 2011-03-14
US201161487263P 2011-05-17 2011-05-17
US61/487,263 2011-05-17
PCT/US2012/024020 WO2012109162A1 (en) 2011-02-07 2012-02-06 Lipoprotein complexes and manufacturing and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015271986A Division AU2015271986B2 (en) 2011-02-07 2015-12-21 Lipoprotein complexes and manufacturing and uses thereof

Publications (2)

Publication Number Publication Date
AU2012214672A1 AU2012214672A1 (en) 2013-05-02
AU2012214672B2 true AU2012214672B2 (en) 2015-10-01

Family

ID=45592833

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2012214672A Active AU2012214672B2 (en) 2011-02-07 2012-02-06 Lipoprotein complexes and manufacturing and uses thereof
AU2015271986A Active AU2015271986B2 (en) 2011-02-07 2015-12-21 Lipoprotein complexes and manufacturing and uses thereof
AU2018203258A Active AU2018203258B9 (en) 2011-02-07 2018-05-10 Lipoprotein complexes and manufacturing and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2015271986A Active AU2015271986B2 (en) 2011-02-07 2015-12-21 Lipoprotein complexes and manufacturing and uses thereof
AU2018203258A Active AU2018203258B9 (en) 2011-02-07 2018-05-10 Lipoprotein complexes and manufacturing and uses thereof

Country Status (27)

Country Link
US (9) US20120232005A1 (https=)
EP (4) EP2673296B1 (https=)
JP (5) JP6219170B2 (https=)
KR (1) KR20140053848A (https=)
CN (4) CN105294859A (https=)
AU (3) AU2012214672B2 (https=)
CA (1) CA2826158A1 (https=)
CY (2) CY1121317T1 (https=)
DK (3) DK2673296T3 (https=)
ES (3) ES2994009T3 (https=)
HR (2) HRP20190138T1 (https=)
HU (2) HUE042314T2 (https=)
IL (1) IL227634B (https=)
IN (1) IN2013DN07828A (https=)
LT (2) LT2673296T (https=)
MX (2) MX343907B (https=)
PH (2) PH12013501644A1 (https=)
PL (2) PL2673296T3 (https=)
PT (2) PT2767546T (https=)
RS (2) RS58275B1 (https=)
RU (2) RU2017126088A (https=)
SG (2) SG10201801372YA (https=)
SI (2) SI2673296T1 (https=)
SM (2) SMT201900045T1 (https=)
TW (2) TW201737935A (https=)
WO (1) WO2012109162A1 (https=)
ZA (1) ZA201305628B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
MX2012014928A (es) 2010-06-30 2013-03-22 Csl Ltd Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma.
EP2673296B1 (en) 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses thereof
US9125943B2 (en) * 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
JP2016509068A (ja) * 2013-02-28 2016-03-24 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ クロマチン欠損細胞培養採取物からの抗体のクロマトグラフィー精製
JP6438417B2 (ja) 2013-03-15 2018-12-12 セレニス セラピューティクス ホールディング エスアー スフィンゴミエリンおよびジヒドロスフィンゴミエリンの合成のための方法
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
EP3418290A1 (en) 2013-08-08 2018-12-26 CSL Ltd. Contaminant removal method
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
KR101671580B1 (ko) * 2014-08-26 2016-11-02 영남대학교 산학협력단 미녹시딜 수용액 제조방법
WO2016123365A1 (en) 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
WO2016154544A1 (en) 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2016154542A2 (en) * 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for treating cardiovascular related disorders
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3490579B1 (en) 2016-07-27 2025-09-10 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
WO2018029505A1 (en) 2016-08-11 2018-02-15 Cerenis Therapeutics Holding Sa Cer-001 therapy for treating familial primary hypoalphalipoproteinemia
CN110730668A (zh) * 2017-01-23 2020-01-24 Hdl治疗公司 用于治疗胆固醇相关的疾病的方法
ES2681124B1 (es) 2017-03-08 2019-06-19 Fund Imdea Alimentacion Usos medicos de la apolipoproteina a y de activadores de la misma
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
US12220462B1 (en) 2018-02-13 2025-02-11 Abionyx Pharma Sa Complexes for delivery of cyclic dinucleotides
EP3818078B1 (en) * 2018-07-03 2024-02-28 Bristol-Myers Squibb Company Methods of producing recombinant proteins
JP2020138941A (ja) * 2019-02-28 2020-09-03 国立研究開発法人理化学研究所 バイセル及びその利用
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
AU2020388572A1 (en) 2019-11-20 2022-05-26 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
US20220392065A1 (en) 2020-01-07 2022-12-08 Cleerly, Inc. Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
US11501436B2 (en) 2020-01-07 2022-11-15 Cleerly, Inc. Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
US11969280B2 (en) 2020-01-07 2024-04-30 Cleerly, Inc. Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
WO2021209808A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Cer-001 therapy for treating kidney disease
KR20230004605A (ko) 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
IL297046A (en) 2020-04-16 2022-12-01 Abionyx Pharma Sa Treatment of kidney disease using cer-001
MX2023003877A (es) 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
EP4259280A4 (en) * 2020-12-11 2025-02-12 The Regents Of The University Of Michigan Compositions and methods for preventing, attenuating, and treating medical conditions with shdl nanoparticles
WO2022150631A1 (en) * 2021-01-08 2022-07-14 Hdl Therapeutics, Inc Systems and methods for reducing low attenuation plaque and/or plaque burden in patients
KR20240018430A (ko) * 2021-04-15 2024-02-13 아비오닉스 파마 에스에이 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용
EP4340849A4 (en) * 2021-05-19 2025-04-16 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
US12406365B2 (en) 2022-03-10 2025-09-02 Cleerly, Inc. Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination
US20250217981A1 (en) 2022-03-10 2025-07-03 Cleerly, Inc. Systems, methods, and devices for image-based plaque analysis and risk determination
US20250143657A1 (en) 2022-03-10 2025-05-08 Cleerly, Inc. Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination
US12440180B2 (en) 2022-03-10 2025-10-14 Cleerly, Inc. Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3247588A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
CN120092013A (zh) 2022-06-28 2025-06-03 阿比奥尼克斯制药公司 用于合成鞘磷脂的化合物和方法
KR20240009061A (ko) * 2022-07-13 2024-01-22 (재)씨젠의료재단 혈청 내 다중 아포지단백질의 직접정량 방법
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100567A1 (en) * 2005-03-24 2006-09-28 Cerenis Therapeutics S.A. Charged lipoprotein complexes and their uses
WO2008104890A2 (en) * 2007-02-28 2008-09-04 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein
WO2010093918A1 (en) * 2009-02-16 2010-08-19 Cerenis Therapeutics Sa Apolipoprotein a-i mimics

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
AU587989B2 (en) 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
WO1986004144A1 (en) 1984-12-31 1986-07-17 International Genetic Engineering, Inc. Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
GB8625435D0 (en) 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
IT1229996B (it) 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
WO1993000443A1 (en) 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
US5408038A (en) 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
WO1994010322A1 (en) 1992-10-29 1994-05-11 Board Of Regents, The University Of Texas System Adenovirus-mediated ldl receptor gene transfer and targeting
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5643757A (en) 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
JP3754072B2 (ja) 1994-03-22 2006-03-08 リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド 摂食抑制ペプチド
IL109558A (en) 1994-05-04 2004-08-31 Yissum Res Dev Co DNA structures Derived from the SV40 virus that include DNA sequences External
US5932536A (en) 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
GB9919713D0 (en) 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
WO2001014529A1 (en) 1999-08-25 2001-03-01 Immunex Corporation Compositions and methods for improved cell culture
KR100545945B1 (ko) 2000-07-03 2006-01-25 갈라 디자인, 인크. 발현 벡터
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
US20030224415A1 (en) 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
EP1299556A2 (en) 2000-07-03 2003-04-09 Gala Design, Inc. Host cells containing multiple integrating vectors
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
EP2343317A1 (en) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
DK1345959T3 (da) 2000-11-20 2011-09-05 Univ Illinois Membranscaffoldproteiner
JP2005505494A (ja) 2001-02-23 2005-02-24 イミュネックス・コーポレーション 活性タンパク質の回収増加
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
CA2457840C (en) 2001-08-20 2011-10-11 Zlb Bioplasma Ag Hdl for the treatment of stroke and other ischemic conditions
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
AU2003239489A1 (en) * 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
EP1545576A2 (en) 2002-07-30 2005-06-29 Esperion Therapeutics Inc. Methods of using non-human animal apoliprotein a-i protein
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
DK1641421T3 (en) * 2003-07-03 2019-03-11 Hdl Therapeutics Inc Methods and apparatus for producing HDL particle derivatives of reduced lipid content
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
CN101076541A (zh) * 2004-07-16 2007-11-21 塔夫茨大学信托人 载脂蛋白a1模拟物及其用途
WO2006012632A2 (en) 2004-07-23 2006-02-02 Xencor, Inc. Apolipoprotein a-1 derivatives with altered immunogenicity
AU2006282722A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holdings S.A. Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
US20110059549A1 (en) * 2007-05-09 2011-03-10 Coleman Matthew A Methods and systems for producing nanolipoprotein particles
EP2522674A1 (en) 2007-08-17 2012-11-14 CSL Behring GmbH Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
EA201070517A1 (ru) * 2007-10-23 2010-12-30 Дзе Кливленд Клиник Фаундейшн Устойчивый к окислителям аполипопротеин а-1 и пептиды-миметики
EP2305309A2 (en) 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
US10525152B2 (en) * 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
EP2673296B1 (en) 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses thereof
AU2012236889A1 (en) * 2011-03-25 2013-05-09 The Trustees Of Columbia University In The City Of New York Pegylated human HDL particle and process for production thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100567A1 (en) * 2005-03-24 2006-09-28 Cerenis Therapeutics S.A. Charged lipoprotein complexes and their uses
WO2008104890A2 (en) * 2007-02-28 2008-09-04 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein
WO2010093918A1 (en) * 2009-02-16 2010-08-19 Cerenis Therapeutics Sa Apolipoprotein a-i mimics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LAW, S. W., et al., Proceedings of the National Academy of Sciences, USA, 1984, vol. 81, pages 66-70 *
SCHMIDT, H. H.-J., et al., Protein Expression and Purification', 1997, vol. 10, pages 226-236 *

Also Published As

Publication number Publication date
HUE042314T2 (hu) 2019-06-28
JP7009559B2 (ja) 2022-01-25
IL227634B (en) 2020-05-31
SG10201801372YA (en) 2018-04-27
TW201240671A (en) 2012-10-16
RS58275B1 (sr) 2019-03-29
AU2015271986A1 (en) 2016-01-21
US20240000887A1 (en) 2024-01-04
NZ613524A (en) 2015-10-30
US20250302916A1 (en) 2025-10-02
JP6219170B2 (ja) 2017-10-25
AU2012214672A1 (en) 2013-05-02
PT2767546T (pt) 2019-01-28
US20230372441A1 (en) 2023-11-23
US11969456B2 (en) 2024-04-30
SI2673296T1 (sl) 2019-03-29
US11998587B2 (en) 2024-06-04
RU2627173C2 (ru) 2017-08-03
US20190298800A1 (en) 2019-10-03
US20120232005A1 (en) 2012-09-13
DK2767546T3 (en) 2019-02-04
HK1198834A1 (en) 2015-06-12
EP4400511A3 (en) 2024-09-04
EP2767546B1 (en) 2018-10-17
US11376309B2 (en) 2022-07-05
US12364735B2 (en) 2025-07-22
US9187551B2 (en) 2015-11-17
CN105288589A (zh) 2016-02-03
EP3466969A1 (en) 2019-04-10
AU2015271986B2 (en) 2018-02-22
TW201737935A (zh) 2017-11-01
LT2767546T (lt) 2019-02-25
EP2767546A1 (en) 2014-08-20
IN2013DN07828A (https=) 2015-07-03
RU2017126088A (ru) 2019-01-31
WO2012109162A1 (en) 2012-08-16
CN103443123B (zh) 2020-05-29
US20150152164A1 (en) 2015-06-04
AU2018203258B9 (en) 2021-01-07
AU2018203258A1 (en) 2018-05-31
CY1121317T1 (el) 2020-05-29
CN107337728A (zh) 2017-11-10
KR20140053848A (ko) 2014-05-08
ES2716349T3 (es) 2019-06-12
ZA201305628B (en) 2014-04-30
PH12013501644A1 (en) 2013-10-14
US10328119B2 (en) 2019-06-25
AU2018203258B2 (en) 2020-12-10
MX2013009083A (es) 2014-02-03
DK3466969T3 (da) 2024-07-22
HRP20190072T1 (hr) 2019-03-08
PT2673296T (pt) 2019-01-31
MX355159B (es) 2018-04-06
HUE041797T2 (hu) 2019-05-28
DK2673296T3 (en) 2019-02-18
ES2717455T3 (es) 2019-06-21
ES2994009T3 (en) 2025-01-15
LT2673296T (lt) 2019-02-25
CN107337728B (zh) 2023-05-23
SMT201900045T1 (it) 2019-02-28
EP2673296A1 (en) 2013-12-18
JP6720126B2 (ja) 2020-07-08
JP2022050603A (ja) 2022-03-30
MX343907B (es) 2016-11-28
US20220362336A1 (en) 2022-11-17
RS58243B1 (sr) 2019-03-29
CA2826158A1 (en) 2012-08-16
PL2767546T3 (pl) 2019-04-30
JP2020176122A (ja) 2020-10-29
US20160095901A1 (en) 2016-04-07
EP4400511A2 (en) 2024-07-17
US10322163B2 (en) 2019-06-18
EP3466969B1 (en) 2024-05-08
CN103443123A (zh) 2013-12-11
SI2767546T1 (sl) 2019-03-29
SG192693A1 (en) 2013-09-30
PL2673296T3 (pl) 2019-03-29
SMT201900194T1 (it) 2019-05-10
CN105294859A (zh) 2016-02-03
EP2673296B1 (en) 2018-10-24
PH12016500191A1 (en) 2017-10-18
US20140213501A1 (en) 2014-07-31
JP2014506884A (ja) 2014-03-20
JP2024170492A (ja) 2024-12-10
CY1121318T1 (el) 2020-05-29
HRP20190138T1 (hr) 2019-03-22
JP2018076286A (ja) 2018-05-17
IL227634A0 (en) 2013-09-30
RU2013139066A (ru) 2015-03-20

Similar Documents

Publication Publication Date Title
US11998587B2 (en) Lipoprotein complexes and manufacturing and uses thereof
HK40113633A (en) Lipoprotein complexes and manufacturing and uses thereof
HK1198834B (en) Lipoprotein complexes and manufacturing and uses therof
HK1192266A (en) Lipoprotein complexes and manufacturing and uses thereof
HK1192266B (en) Lipoprotein complexes and manufacturing and uses thereof
NZ613524B2 (en) Lipoprotein complexes and manufacturing and uses thereof

Legal Events

Date Code Title Description
CB Opposition filed

Opponent name: CSL LIMITED

CW Opposition withdrawn - proceed to grant

Opponent name: CSL LIMITED

FGA Letters patent sealed or granted (standard patent)